Medications That Regulate Pregnane X Receptor: A Systematic Review of Current Evidence Authors: Petra Czarniak, Rachael Moorin, Jeff Hughes, Karl Gruber, David Youens Published: 2026 ABSTRACT ABSTRACTThe pregnane X receptor (PXR) gene encodes a ligand‐activated protein involved with the metabolism and excretion of drugs, toxins, and other xenobiotics. The PXR protein is also an orphan nuclear receptor with a broad spectrum of potential ligands, including common prescription drugs, that can act as agonists or antagonists. Once activated, PXR upregulates several target genes involved in xenobiotic metabolism and can influence lipid and glucose metabolism, as well as the metabolism of commonly used drugs. In this review we searched the primary literature for articles reporting on drugs that regulate PXR and discuss potential clinical implications. Using the databases CINAHL, Embase, Medline, Scopus and Web of Science, we searched for terms related to PXR, following PRISMA guidelines. We screened 12 236 studies, 101 of which met the inclusion criteria, and included a further 46 research and review articles. We identified 42 studies reporting on prescription medications and 40 on non‐prescription medications that regulate PXR as agonists or antagonists, and 47 studies reporting both beneficial and detrimental PXR‐mediated effects of drugs on specific diseases, including different cancers, metabolic diseases, and inflammatory conditions, among others. We conclude that PXR is regulated by a broad range of drugs. Downstream effects of this regulation affect different diseases, leading to clinically relevant outcomes, such as altered efficacy of drugs or changes to the pathophysiology of a disease. Understanding and managing the agonist or antagonist role of drugs on PXR holds great potential to improve the health outcomes of different diseases. However, more information is needed about the potency of known PXR regulators. Introduction We are constantly exposed to a wide range of chemicals or external compounds, commonly known as xenobiotics, which include anything from environmental pollutants to drugs or dietary compounds. To deal with these chemicals, our body has developed complex molecular pathways, involving different genes and systems. Over the past decades, experimental and epidemiological studies have identified nuclear receptors (NRs) as key players in our body's response to xenobiotics. NRs are an ancient family of proteins found across all vertebrates, where they play important roles as ligand‐activated transcription factors, influencing different gene networks [1]. In humans, NRs regulate gene expression in a wide range of tissues, affecting diverse physiological processes, such as development, metabolism, reproduction, immune response, and neuronal function. From a structural perspective, a common trait of NRs is the presence of a DNA‐binding domain and a ligand‐binding domain (LBD), which allows for the control of gene networks following ligand binding. Through their LBD, NRs can respond to one or more endogenous or exogenous ligands, an important feature used in their classification [2]. Among orphan receptors, the pregnane X receptor (PXR) is a NR found in different parts of the body and is known for its broad ligand spectrum, which makes it an ideal sensor for xenobiotics. PXR is a ligand‐activated NR protein that regulates key detoxification pathways involved with the metabolism and excretion of a wide range of drugs, toxins, and other molecules [3]. PXR is primarily expressed in the liver, small intestine, rectum, colon, and bladder, among other tissues [4]. All these locations represent parts of the body that are commonly in contact with xenobiotics. Another important feature of PXR lies in its structure. Unlike other NRs, PXR harbors a LBD that is largely hydrophobic and structurally flexible, allowing for conformational changes to accommodate structurally diverse molecules [5]. For this reason, PXR has affinity with a diverse range of molecules, including antibiotics, calcium channel blockers, steroids, dietary supplements, environmental pollutants, antimycotics, protease inhibitors, and statins, among others [6]. From a functional perspective, when no ligand is present, PXR remains in a repressed state, where it does not alter the function of target genes. When a ligand binds to PXR's LBD, PXR translocates from the cytoplasm to the nucleus of the cell, where it binds with a co‐activator, such as the xenobiotic response element (XRE) or with the retinoid X receptor (RXR) [7]. Once activated, PXR can upregulate several target genes involved in drug/xenobiotic metabolism. Among these target genes, the most important is cytochrome P450 3A4 (CYP3A4), which is thought to be responsible for the metabolism of about 50% of all drugs and xenobiotics [8]. In addition to CYP3A4, PXR regulates the expression of other relevant drug/xenobiotic‐metabolizing enzymes such as CYP2C9, CYP2B6, CYP2C19, CYP3A5, uridine diphosphate‐glucuronosyltransferase 1A1 (UGT1A1), and sulfotransferase 2A1 (SULT2A1), as well as drug transporters such as Multidrug Resistance Protein 1 (MDR1; also known as P‐glycoprotein or Pgp) and ATP Binding Cassette Subfamily C Member 2 (MRP2) [9]. More broadly, PXR function and modulation has been linked to a wide range of disorders, diseases, and health outcomes due to its effects on downstream gene pathways. PXR can also impact lipid and glucose metabolism, leading to altered energy homeostasis, contributing to insulin resistance and metabolic dysfunction [10]. PXR is also known to bind to a broad range of environmental molecules, such as cholesterol, statins, endocrine disruptors, certain components of herbal medicines, steroids, pesticides, and other molecules [11]. Many of these chemicals act as PXR agonists, leading to PXR activation with different degrees of potency. More broadly, altered expression of PXR has been implicated in a range of diseases, including cancer, diabetes, inflammatory bowel disease (IBD), and liver disease [12, 13, 14]. While PXR affects the function and metabolism of common drugs, activation of PXR can occur by a vast array of drugs that can bind to PXR's LBD, leading to the induction of CYP3A4. This induction is followed by the expression of drug‐metabolizing enzymes that ultimately influence the efficacy or toxicity of some drugs. Among the multiple medications identified as strong PXR ligands, studies have reported on antimicrobials like rifampicin, clotrimazole, and ritonavir; the antineoplastic drugs cyclophosphamide, taxol, and ifosfamide; the anti‐inflammatory agent dexamethasone; the withdrawn diabetes drug troglitazone; the antihypertensive drugs nifedipine and spironolactone; and the sedatives glutethimide and phenobarbital [6, 15]. To our knowledge, no systematic review to date has focused on medications that regulate PXR. Without such a review, it is impossible to accurately assess the potential impact of medications on PXR function and their potential clinical relevance. In this review, we search the primary literature for articles reporting on the regulatory effect of a vast range of medications, including both prescription and non‐prescription drugs on PXR. We summarize the key findings of all research studies identified and discuss the potential implications of these PXR modulators in health outcomes. More specifically, we aim to answer the following questions: (i) which medicines in current use interact with PXR in humans, which are agonists, and which are antagonists; (ii) what information is available regarding the potency of these PXR modulators; and (iii) what impact or potential impact do these drugs have on health outcomes? Methods Search Strategy and Selection Criteria This systematic review was prospectively registered on PROSPERO (CRD42024558391) and our methodology was developed in accordance with the PRISMA 2020 statement. Briefly, one author (K.G.) searched all databases, without limitation in publication date, for research and review articles reporting on medications (both prescription and non‐prescription) that regulate PXR as agonists or antagonists. Full search terms used, and databases searched are shown in the Tables S1 and S2, respectively. A list of acronyms and abbreviations used is provided in Table S3. Two authors (K.G., P.C.) screened the initial search results for relevant articles. Eligible publications involved studies that used human subjects or human‐derived models and were published in English. Data Collection and Risk of Bias Assessment Data collection was performed manually, applying the inclusion and exclusion criteria described above, using the COVIDENCE online tool. Data extracted from each eligible publication included: first author, year of publication, journal, type of PXR modulator (antagonist or agonist), EC50 values if available, name of the medication and any linked diseases. EC50 values are a standard measure of potency and represent the concentration of a bioactive compound that induces a response halfway between the baseline and maximum, in a given period of time. Two authors (K.G. and P.C.) assessed the risk of bias using a modified version of Cochrane's risk of bias tool. Any disagreements between the two authors were resolved through discussion. Role of the Funding Source The funder had no role in the study design, in the collection, or interpretation of data, or writing of the report. Results We identified a total of 12 236 studies across all databases that included relevant terms, after removing duplicated records (Figure 1). Manual screening was performed for these studies by two reviewers (K.G. and P.C.), following our inclusion and exclusion criteria described above. Further screening was performed ad hoc, removing studies found not relevant upon further inspection of the content. This approach resulted in a total of 101 studies, which were primarily used in this review. Beyond these studies, we also included 46 additional research and review articles, which discussed different implications of PXR regulation by medications. PRISMA Flow Diagram, describing key steps followed to identify selected studies. Diagram created with online tool available at https://estech.shinyapps.io/prisma_flowdiagram/. Medications That Regulate PXR Function We identified 42 studies that reported on prescription medications that regulate PXR either as agonists or antagonists (Tables S4 and S5). These studies reported only on the PXR agonist or antagonist function of specific medications, without focusing on specific diseases or healthcare applications. We identified 85 prescription medications that acted as PXR agonists (Table S4), nine that acted as antagonists (Table S5). We also identified 81 non‐prescription medications that acted as agonists (Table S6) and 9 non‐prescription medications that acted as antagonists (Table S7). Where available, we also provide EC50 values for each medication identified as a PXR regulator (Table S8). The supplementary tables of PXR agonists comprise approved prescription medications (Table S4, n = 85) and Traditional Chinese Medicine (TCM) herbs and other non‐prescription agonists (Table S6, n = 81). A full master list of all reported PXR agonists, including investigational compounds and active metabolites with extended pharmacological detail, is provided separately (Table S8). Quantitative EC50 values are provided where available from peer‐reviewed publications. Notably, EC50 data is largely absent for natural products and TCM herbs, as many of these compounds were studied only in screening assays without full dose–response characterization. Among approved medications, Table S8 provides EC50 values for 49 compounds, including classical PXR inducers such as rifampicin and taxane anticancer drugs such as paclitaxel [16]. Cancer‐related drugs were the most common type of medication identified among these studies, and included the tyrosine kinase inhibitors gefitinib and dabrafenib, which acted as PXR agonists in human‐derived cells and led to the activation of downstream genes such as CYP3A4 and CYP2B6 [17, 18]. The common antiestrogen tamoxifen, used in the treatment and chemoprevention of breast cancer, was identified as a PXR agonist in human hepatocytes, also leading to the induction of CYP3A4 expression [19]. Finally, Mani et al. [20] identified the chemotherapy drugs paclitaxel and ixabepilone as PXR agonists and inductors of CYP3A4 protein expression in HepG2 cells. Among antivirals and antibacterial compounds, we identified the antibacterial walrycin A, which acted as a PXR agonist, and the HIV protease inhibitor nelfinavir, identified as a partial agonist and competitive antagonist of PXR [21, 22]. Also reporting on HIV drugs, Sharma et al. [23] identified the HIV drugs rilpivirine and etravirine as PXR agonists in HepG2 cells. Beyond HIV drugs, we identified a study reporting on the antibiotics nafcillin, dicloxacillin, cefradine, tetracycline, sulfixoxazole, erythromycin, clindamycin, and griseofulvin as potential PXR agonists, based on their ability to induce CYP3A4 expression [24]. Also working on antivirals, Cheng et al. [25] provided evidence of the structural basis for PXR activation by the reverse transcriptase inhibitor PNU‐142721, currently an experimental drug. Beyond antivirals, Chen et al. [26] showed that the synthetic progestogen megestrol acetate acted as a PXR agonist on primary human hepatocytes, and Li et al. [27] identified the barbiturate drug phenobarbital as a PXR agonist in HepaRG cell lines. Drocourt et al. [28] used primary human hepatocyte cultures to identify four calcium channel modulators (CCM) that acted as PXR regulators. This study found that nifedipine, nicardipine, and isradipine acted as PXR agonists, as did the experimental compound BK8644 (Bay K8644). Singh et al. [29] identified two anti‐diabetic drugs, rosiglitazone and pioglitazone, that acted as PXR agonists and induced expression of the genes CYP3A4, UGT1A1, and MDR1. Bosentan, a medication used to treat the symptoms of pulmonary arterial hypertension, was identified as a PXR agonist (EC50 of 4.8–14.1 μM reported), alongside the diabetes drug glibenclamide, also identified as a PXR agonist [30]. Across all the studies identified in this review, EC50 values reported for PXR agonists ranged between 0.25 μM (reported for felodipine) and > 100 μM (reported for estriol) (Tables S4, S6, and S8). Among non‐prescription medications, we identified 40 studies reporting on the PXR agonists and antagonists [7, 23, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68] (Tables S6 and S7). These studies found various natural compounds that acted as PXR regulators. Among these, capsaicin, the active pungent compound in chili peppers, and Alisol B 23‐acetate, the active compound found in the rhizomes of the medicinal plant Alisma orientale, were identified as PXR agonists [69, 70]. Ban‐Lan‐Gen, a traditional medicine made of the dry roots of indigo plants (Polygonum tinctorium, Isatis indigotica, Isatis tinctoria, and Strobilanthes cusia), was identified as a potential PXR agonist based on the activation of CYP3A4. The effect reported for Ban‐Lan‐Gen was also found for one of its active ingredients, indirubin [71]. Also focusing on natural medications, a study led by Lau et al. [72] identified Ginkgo biloba as well as one of its active components, ginkgolide A, as PXR agonists, whereas Manda et al. [73] reported that the extract of Mitragyna speciosa, a traditional medicinal plant, acted as a PXR agonist. In contrast, Xu et al. [74] identified the natural compound Z‐guggulsterone as a PXR antagonist. This compound is the main active component of the herbal extract guggulipid, obtained from the tree Commiphora mukul. We also identified a single study that reported on the PXR regulatory effect of 30 medications used in TCM. Yu et al. [31] identified Ginkgo biloba, Ligusticum chuanxiong, Chinese angelica, prepared Rehmannia root, Epimedium brevicornum, Atractylodes macrocephala, Schisandra chinensis, Paeonia lactiflora, Ophiopogon japonicus, Polygonum multiflorum, Coptis chinensis, Artemisia scoparia, Trichosanthes kirilowii, Silybum marianum, Gardenia fruit, and Lycium chinense as PXR agonists. Also reporting on multiple PXR regulators, a study by Kluth et al. [75] identified the extracts from clove, thyme, curcumin, and resveratrol as PXR agonists. Comparable results are reported by Raucy et al. [76], who showed that the extract from the root of the Kava plant (Piper methysticu) acted as a PXR agonist. Focusing on the TCM red ginseng and Shenmai injection, Zhang et al. [77] identified panaxytriol, the main bioactive ingredient of these medications, as a PXR agonist. A study by Awortwe et al. [78] reported that the extract of Echinacea purpurea , a medicinal plant used for the treatment of cold and influenza, acts as a PXR agonist, whereas Rühl et al. [79] reported on the PXR agonist effect of carotenoids. Finally, Wang et al. [32] identifies the phytoestrogen coumestrol as a PXR antagonist. PXR Regulation and Clinical Applications We identified 46 studies reporting on the potential clinical implications of PXR regulation, and their downstream effect on gene function and the pathophysiology of specific diseases or conditions [12, 13, 14, 33, 34, 35, 36, 37, 38, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 56, 57, 58, 59, 61, 64, 67, 68, 80]. In Table 1, we summarize data from selected studies encompassing different diseases and clinical outcomes mediated by PXR regulation by different medications, including prescription drugs and natural compounds used as medicine. TABLE 1Selected studies reporting on the effect of PXR regulation by medications on specific diseases and other conditions.Disease/conditionPXR regulationOutcomeSourceCholestatic liver injuryPXR activation via Schisandrol BAccelerated metabolism of bile acids, increased bile acid efflux into the intestine, and increased hepatic expression of PXR‐regulated genes involved in bile acid homeostasis[33]CirrhosisPXR activation via Ginkgolide‐AImproved tight junction proteins expression and reduce bacterial translocation[34]ColitisPXR activation via St. John's WortPrevention of dextran sulfate sodium‐induced colitis[35]Drug resistance in Mycobacterium tuberculosis PXR inhibition via ketoconazoleRestoration of rifampicin anti‐TB activity[36]High blood pressurePXR activation via rifampinElevated mean systolic and diastolic 24‐h blood pressure and mean heart rate, compared to controls[37]HyperlipidemiaPXR activation via quetiapineIncreased intestinal expression of cholesterol transporter Niemann‐Pick C1‐Like 1 (NPC1L1) and microsomal triglyceride transfer protein (MTP), which led to increased intestinal lipid absorption[38]Impaired detoxificationPXR inhibition via metforminSuppressed expression of CYP3A4 in hepatocytes and supressed the upregulation of Cyp3a11 mRNA in the liver and intestine[39]Impaired drug metabolismPXR inhibition via ketoconazoleDelayed metabolism of the anesthetic tribromoethanol[40]Impaired hepatic glucose metabolismPXR activation via atorvastatin and rifampicinDownregulated expression of the genes GLUT2 and HNF4α, involved in glucose metabolism[41]Inflammatory bowel diseasePXR activation via Notoginsenoside R1Decreased activity of myeloperoxidase, decreased production of cytokines, lower expression of proinflammatory genes[42]Liver regenerationPXR activation via oleanolic acidIncreased liver mass restoration[43]Lung cancerPXR inhibition via SPA70Inhibited tumor cell growth, migration and invasion[44]Ovarian Cancer PXR inhibition via paclitaxel; PXR inhibition via siRNA and ketoconazole Enhanced drug efficacy; Enhanced cancer cell growth inhibition and apoptosis [45, 46]Prostate cancerPXR activation via leflunomide and phenethyl isothiocyanatEnhanced antitumor activity of platinum compounds[47]Solid tumorsPXR inhibition via ketoconazole and phenethyl isothiocyanateEnhanced the antitumor activity of cisplatin[47]Wound healingPXR activation via indirubinAccelerated wound closure, upregulated migratory capacity of keratinocytes[48] Selected studies reporting on the effect of PXR regulation by medications on specific diseases and other conditions. PXR inhibition via paclitaxel; PXR inhibition via siRNA and ketoconazole Enhanced drug efficacy; Enhanced cancer cell growth inhibition and apoptosis For cancer, we identified 12 studies that reported on the PXR regulatory effects of medications and their clinical applications [18, 20, 26, 44, 45, 46, 47, 49, 50, 51, 52, 53]. Briefly, these studies provided evidence that PXR activation or inhibition by cancer drugs can affect different aspects of cancer treatment or pathophysiology. For example, the development of multidrug resistance was reported to occur through PXR‐mediated mechanisms, such as the accumulation of Pgp, alteration in the gene expression patterns of cancer stem cells, and through other mechanisms [49, 51, 52, 54], inhibition of tumor growth was observed after treatment with a PXR antagonist alongside the lung cancer drug paclitaxel [44, 46]. Other studies showed that PXR regulation enhanced the effect of cancer medications through the regulation of different genes targeted by PXR [45, 47]. We also identified studies reporting a beneficial effect of PXR regulation in liver pathologies. For example, Zeng et al. [33] showed that the non‐prescription medication SolB acted as a PXR agonist, inducing the expression of Cyp3a11, Ugt1a1, and Oatp2, involved in acid homeostasis. This outcome led to improved metabolism of bile acids and promoted intestinal bile acid efflux. Mohandas et al. [34] found comparable results for ginkgolide‐A, a non‐prescription medication and PXR agonist. Ginkgolide‐A led to the activation of PXR in the liver and small intestine, which resulted in reduced levels of inflammatory markers. According to the authors of this study, the purported mechanism driving this effect involved improvements in tight junction integrity in the intestinal wall and reduced bacterial translocation. Murayama et al. [55] found that PXR activation by the prescription medication thalidomide led to improved hepatic enzyme metabolism, whereas Sun et al. [56] found that PXR activation with pregnenolone 16α carbonitrile in primary cultures of human hepatocytes suppressed key inflammatory mediators. In contrast, in a retrospective study Amer et al. [57] found that PXR activation likely played a significant role in early allograft dysfunction among patients who had received a liver transplant. However, no potential mechanism was proposed for this potential effect of PXR activation. Similar to the effect reported in liver pathologies, PXR activation has been shown to exert a protective effect on patients and animal models of IBD [42]. While the mechanisms involved are still not fully resolved, evidence so far points to regulatory effects of PXR on nuclear factor kappa B (NF‐κB) signaling, which results in reduced expression of proinflammatory cytokines. A good example of the effect of PXR activation in inflammatory processes can be seen in two studies using animal models of IBD. Studies show that the non‐prescription medications Notoginsenoside R1 and Tanshinone IIA activated PXR and led to the downregulation of genes involved in inflammatory processes [42, 58]. As a result, their IBD models showed a reduction in inflammatory markers characteristic of IBD. A study by Yan et al. [35] showed that the medicinal herb St. John's Wort activated PXR in animal models of IBD and prevented dextran sulfate sodium (DSS)‐induced IBD. Similar results were reported by Deuring et al. [59] on the prescription antibiotic, and PXR agonist, rifampicin. In their study, the authors show that treating colonic biopsies from Crohn's disease patients with rifampicin resulted in high levels of epithelial colonic PXR activation and low expression levels of the gene NF‐κB, a master regulator of inflammatory responses. NF‐κB signaling is often dysregulated in IBD patients, and the findings of this study shed light into a potential mechanism linking PXR activation to IBD via NF‐κB/PXR signaling. From a clinical perspective, these results suggest that targeting PXR regulation may translate into therapeutic benefits, particularly for IBD patients exhibiting epithelial hyper‐activation of NF‐κB signaling. More broadly, the findings of these studies suggest that PXR signaling is part of an anti‐inflammatory mechanism that can curb epithelial inflammation in IBD patients. Deuring et al. [59] also suggest that stimulation of PXR in IBD patients has clinical implications due to the reported effect of PXR on bone mineral homeostasis [60]. Our review also identified 11 studies reporting on the role of PXR regulation in different aspects of metabolism, including glucose and drug metabolism [26, 38, 39, 41, 42, 43, 61, 62, 63, 64, 65]. Most studies identified relied on cell and animal models, showing the regulatory effect of drugs like metformin, atorvastatin, phenobarbital, rifampicin, or quetiapine on PXR and the downstream effect of this regulation in genes involved in the metabolism of glucose, drugs, xenobiotics [39, 41, 61, 62]. For the purported mechanisms, these studies reported the involvement of PXR regulation in the altered expression of genes involved in drug and xenobiotic metabolism, such as CYP3A4 and Cyp3a11 [39], glucose metabolism, such as GLUT2 and GCK [61] and genes involved in intracellular homeostasis [62]. One study identified used human subjects to address the role of PXR in glucose metabolism. Rysä et al. [64] conducted a randomized, open, placebo‐controlled crossover trial testing the effects of PXR activation on an oral glucose tolerance test (OGTT). The study, involving both healthy human subjects and an animal model, found that the use of a PXR agonist led to elevated glucose levels during the OGTT, compared to placebo. According to the study, their results suggest that PXR agonists can affect glucose tolerance in healthy subjects and lead to postprandial hyperglycemia. We also identified studies reporting on the effect of PXR in the effectiveness of antibacterials such as rifampicin, rifaximin, and rifamycin [36, 66, 67] and improving wound healing in both skin [48] and intestinal epithelial cells [68]. Discussion PXR is a ligand‐activated nuclear receptor overseeing the expression of drug‐metabolizing enzymes and transporter proteins in the human body. Through this process, PXR controls the degradation and excretion of both endobiotic compounds and xenobiotic molecules, such as medications. The metabolism and eventual degradation of medications through the PXR pathway can potentially affect their efficacy and can even lead to drug toxicity and/or drug resistance. But it is now known that the role of PXR in the human body goes beyond xenobiotic detoxification, with studies showing that PXR can influence and regulate different genes, ultimately affecting various biological processes, such as glucose and lipid metabolism, bile acid/cholesterol metabolism, inflammation regulation, Endoplasmic Reticulum stress, autophagy, steroid/endocrine homeostasis, and carcinogenesis [81]. Hence, PXR can potentially play a significant role in different diseases, from diabetes and other metabolic disorders to inflammatory conditions like colitis and IBD, as well as different forms of cancer. In this review, we have identified relevant research studies that report on prescription and non‐prescription medications with a regulatory effect on PXR, either as agonists or antagonists and presented details about their regulatory potency, when available. We have also highlighted clinically relevant implications of PXR regulation by different medications, based on the key findings of the studies identified. Most of the medications identified exert a regulatory effect on PXR as agonists (85 medications identified) compared to antagonists (nine medications identified). The small number of PXR antagonists so far reported may reflect the inherent difficulties of identifying or designing PXR antagonists, primarily driven by the promiscuous ligand‐binding nature of this protein [82]. The potential reach of PXR modulation in health care goes well beyond the conditions discussed above. From altered blood pressure and impaired glucose metabolism, to improved wound healing and reduced hormone production, PXR has been shown to affect a wide range of body functions. However, these reported effects are only backed by a paucity of studies, hinting at the need to further investigate the role of PXR in these processes. Liu et al. [41], for example, showed that atorvastatin and rifampicin activated PXR, which led to the downregulation of genes involved in glucose metabolism. In a 2014 review, Hukkanen et al. discussed the potential role of PXR in diabetes, including the potential role of medications that activate PXR [80]. Among these, the review identifies different drugs that seem associated with either an increase or a reduction in the risk of diabetes. For example, high diabetes risk is reported as being associated with medications like atorvastatin, simvastatin, and rosuvastatin, whereas low or non‐existent risk was associated with the use of pravastatin, lovastatin, and fluvastatin. Given that some of these drugs are known agonists of PXR, including atorvastatin, simvastatin, lovastatin, and fluvastatin, it is suggested that PXR may have a role in the link between these drugs and the onset of diabetes. However, the authors also acknowledge key limitations in our understanding of this putative link between PXR and diabetes. For example, most studies to date on this topic are limited to animal models, with no insights into the potential applicability in humans. Another limitation involves the potential dual activation effect of some medications, which can activate PXR as well as the closely related nuclear receptor constitutive androstane receptor (CAR). CAR also has inherited effects on glucose metabolism, which complicate potential interpretations of the role of PXR [80, 83]. Adverse effects to medications affect millions of patients, with one study estimating 23 million cases of adverse drug reactions occurring between 2012 and 2019 [84]. As reported by the multiple studies identified in this review, a wide range of medications can regulate the function of PXR, affecting the downstream function of different genes. The altered function of these genes can affect metabolic pathways involved with lipid and glucose metabolism, influencing the onset of metabolic disorders like Type 2 Diabetes [41, 85]. From a clinical perspective, the findings of our review hint at the potential role of incorporating information about PXR regulation by medications into current prescribing practices. Informing both clinicians and patients about the potential effect of specific medications on PXR could allow for improved prescribing practices that result in optimal patient health outcomes. Limitations A significant limitation of the studies identified in this review concerns the lack of understanding of the mechanisms behind the purported effects of PXR on disease pathophysiology, drug–drug interactions, or response to treatment. For example, while we found reports supporting the role of PXR modulation in cancer chemotherapy resistance or disease development, there was also a paucity of studies elucidating potential mechanisms involved. Another limitation identified in this review concerns the reporting of PXR potency, usually measured as EC50 values. Less than half of the compounds identified had EC50 values reported. This gap is particularly pronounced for natural products and TCM herbs (Tables S6 and S7), which were typically studied only in high‐throughput screening assays without quantitative dose–response determination. For approved pharmaceutical medications, EC50 data availability was substantially higher, though still incomplete. EC50 values allow for the evaluation of the strength of a PXR agonist or antagonist, which has implications for the interpretation of the expected effects. Expanding the repertoire of PXR ligands with EC50 values is an important path that future studies ought to take, as this information will help translate findings of PXR regulation by specific ligands into clinical applications. Gaps in the Literature The findings of this review also point to several gaps in the literature that future research should address. Most of the studies identified relied on cell‐based or animal models, and human clinical data on PXR‐mediated drug interactions remain scarce. Addressing this translational gap is important before findings on PXR modulation can be incorporated into prescribing practice. The catalogue of PXR antagonists also remains limited relative to agonists, with only 18 antagonists identified across all medications reviewed, compared to 166 agonists. Given the potential therapeutic relevance of PXR inhibition, including in the context of cancer chemotherapy resistance, identifying and characterizing novel PXR antagonists represents an important avenue for future work. Beyond antagonist discovery, dose–response data are absent for the majority of compounds identified, particularly for natural products and traditional herbal medicines, where screening assays have not been followed by quantitative EC50 determination or clinical dose data. Without this information, it is not possible to assess whether PXR activation occurs at clinically relevant concentrations for most of the compounds catalogued in this review. Conclusions Through different mechanisms and pathways, PXR has been shown to be an important regulator of enzymes involved in drug metabolism and drug–drug interactions. At the core of this regulatory feat is PXR's ability to bind to a wide range of ligands, including a myriad of prescription drugs. However, throughout our review, we identify the need to improve the reporting of key measures of PXR—ligand interaction, such as EC50, with a significant number of studies lacking data for this essential measure of potency. There is also a clear need to improve our understanding of PXR ligands that function as antagonists. The paucity of PXR antagonists so far identified hints at the need for further research that identifies new PXR antagonists as well as novel applications. Studies showing the effect of PXR antagonists inhibiting cancer growth are just one example of the potential of these ligands. Author Contributions Petra Czarniak: conceptualization, methodology, investigation (study screening), data curation, risk of bias assessment, supervision, writing – review and editing. Rachael Moorin: conceptualization, funding acquisition, supervision, review and editing. Jeff Hughes: conceptualization, funding acquisition, review and editing. Karl Gruber: methodology, investigation (database searching and study screening), data curation, formal analysis, writing – original draft, writing – review and editing. David Youens: conceptualization, funding acquisition, review and editing. Funding This work was supported by the Western Australian Future Health Research and Innovation (FHRI) Fund, a Western Australian State Government fund. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Table S1: Terms used in search strategy. Table S2: Databases used and studies identified. Table S3: Acronyms used. Table S4: Medications reported as PXR agonists. Table S5: Medications reported as PXR antagonists. Table S6: Non‐Prescription medicines reported as PXR agonists. Table S7: Non‐Prescription medicines reported as PXR antagonists. Table S8: Full list of reported PXR agonists with extended pharmacological details: indications, typical dose range, reported total Cmax, protein binding, published PXR EC50, citation, and notes.